Natera, Inc. $NTRA Shares Purchased by UBS AM a distinct business unit of UBS ASSET MANAGEMENT AMERICAS LLC

UBS AM a distinct business unit of UBS ASSET MANAGEMENT AMERICAS LLC grew its holdings in shares of Natera, Inc. (NASDAQ:NTRA) by 10.7% in the 2nd quarter, Holdings Channel.com reports. The institutional investor owned 833,376 shares of the medical research company’s stock after purchasing an additional 80,440 shares during the period. UBS AM a distinct business unit of UBS ASSET MANAGEMENT AMERICAS LLC’s holdings in Natera were worth $226,220,000 at the end of the most recent quarter.

Other large investors also recently made changes to their positions in the company. Trust Co. of Vermont purchased a new stake in Natera during the 2nd quarter worth $26,000. Elevation Wealth Partners LLC purchased a new position in Natera in the second quarter valued at about $30,000. Reflection Asset Management acquired a new position in shares of Natera during the fourth quarter worth about $29,000. Rakuten Securities Inc. acquired a new position in shares of Natera during the second quarter worth about $35,000. Finally, Palladiem LLC purchased a new stake in shares of Natera in the fourth quarter worth about $31,000. Institutional investors and hedge funds own 99.90% of the company’s stock.

Natera Price Performance

Shares of NASDAQ NTRA opened at $321.96 on Tuesday. Natera, Inc. has a 1-year low of $157.43 and a 1-year high of $343.18. The business’s fifty day moving average price is $286.93 and its two-hundred day moving average price is $234.55. The firm has a market capitalization of $46.41 billion, a PE ratio of -236.73 and a beta of 1.51.

Natera (NASDAQ:NTRA) last posted its earnings results on Thursday, August 6th. The medical research company reported ($0.47) earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of ($0.49) by $0.02. The firm had revenue of $752.75 million during the quarter, compared to analyst estimates of $661.24 million. Natera had a negative net margin of 7.11% and a negative return on equity of 11.38%. Natera’s revenue was up 37.7% on a year-over-year basis. During the same period in the previous year, the business posted ($0.74) EPS. Equities research analysts expect that Natera, Inc. will post -1.02 earnings per share for the current fiscal year.

Wall Street Analyst Weigh In

A number of equities research analysts have recently issued reports on NTRA shares. Robert W. Baird set a $348.00 target price on Natera in a research note on Friday, August 7th. Citigroup upped their price target on Natera from $315.00 to $365.00 and gave the stock a “buy” rating in a report on Thursday, August 13th. Piper Sandler raised their price target on shares of Natera from $249.00 to $363.50 and gave the company an “overweight” rating in a report on Wednesday, August 12th. Morgan Stanley restated an “overweight” rating and set a $355.00 price objective on shares of Natera in a report on Monday, August 10th. Finally, TD Cowen upped their target price on shares of Natera from $325.00 to $340.00 and gave the company a “buy” rating in a research note on Friday, August 7th. Two research analysts have rated the stock with a Strong Buy rating, fifteen have assigned a Buy rating, four have given a Hold rating and one has issued a Sell rating to the company. Based on data from MarketBeat, Natera has an average rating of “Moderate Buy” and an average target price of $319.38.

Insider Activity at Natera

In related news, insider John Fesko sold 6,517 shares of the company’s stock in a transaction dated Monday, August 10th. The shares were sold at an average price of $321.53, for a total value of $2,095,411.01. Following the completion of the sale, the insider owned 197,257 shares of the company’s stock, valued at $63,424,043.21. This represents a 3.20% decrease in their ownership of the stock. The transaction was disclosed in a document filed with the SEC, which is available through the SEC website. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. The sale was made to cover tax withholding obligations related to the vesting of equity awards. Also, CEO Steven Leonard Chapman sold 3,076 shares of the company’s stock in a transaction that occurred on Monday, August 3rd. The stock was sold at an average price of $266.39, for a total transaction of $819,415.64. Following the completion of the sale, the chief executive officer directly owned 99,897 shares of the company’s stock, valued at approximately $26,611,561.83. This represents a 2.99% decrease in their ownership of the stock. The disclosure for this sale is available in the SEC filing. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. The sale was made to cover tax withholding obligations related to the vesting of equity awards. Insiders have sold 103,472 shares of company stock valued at $24,960,134 in the last ninety days. Company insiders own 5.05% of the company’s stock.

Natera Profile

Natera is a global diagnostics company that develops and commercializes cell-free DNA and other genetic testing technologies for clinical applications. The company focuses on three principal areas: reproductive health (including non-invasive prenatal testing and carrier screening), oncology (tumor-informed assays for minimal residual disease and recurrence monitoring), and organ transplantation (cell-free DNA tests to detect allograft injury). Natera combines laboratory testing, proprietary bioinformatics, and clinical reporting to deliver personalized genetic information to clinicians and patients.

Key product offerings include Panorama, a non-invasive prenatal test that screens for fetal chromosomal abnormalities and select single-gene conditions; Horizon carrier screening for inherited conditions; Signatera, a personalized, tumor-informed assay used for detecting minimal residual disease and monitoring treatment response in cancer patients; and Prospera, a donor-derived cell-free DNA test used to assess the risk of organ rejection.